bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Authors: McMillin Douglas W. , Jacobs Hannah M. , Delmore Jake E. , Buon Leutz , Hunter Zachary R. , Monrose Val , Yu Jie , Smith Peter G. , Richardson Paul G. , Anderson Kenneth C. , Treon Steven P. , Kung Andrew L. , Mitsiades Constantine S.
Published: April 2023

PDF file - 116K
Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 7. Changes in signaling upstream of translation initiation complex assembly within 24 hours
Supplementary Table 1 from βIII-Tubulin Regulates Breast Cancer Metastases to the Brain
Authors: Kanojia Deepak , Morshed Ramin A. , Zhang Lingjiao , Miska Jason M. , Qiao Jian , Kim Julius W. , Pytel Peter , Balyasnikova Irina V. , Lesniak Maciej S. , Ahmed Atique U.
Published: April 2023

Primer sequence.
Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 5. Effect of tonicity changes on cell viability
Supplementary Table S1 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Table S1: Forward and Reverse primers used for quantitative pcr analysis of various genes like c-Myc,p53,GAPDH,NONO and U6
Supplementary Table 2 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

Shelf-life of hydrated 50% cholesterol DOPC-PEG-siRNA nanoliposomes at room temperature (RT).
Supplementary Table 1 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

Characterization of DOPC-PEG-siRNA nanoliposomes.
Supplementary Figure 3 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

Immunostimulatory effects and safety of DOPC-PEG-siRNA.
Supplementary Figure Legends and Methods from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Figure Legends and Supplementary Materials and Methods
Supplementary Table 1 from SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
Authors: Sussman Django , Smith Leia M. , Anderson Martha E. , Duniho Steve , Hunter Joshua H. , Kostner Heather , Miyamoto Jamie B. , Nesterova Albina , Westendorf Lori , Van Epps Heather A. , Whiting Nancy , Benjamin Dennis R.
Published: April 2023

Supplementary Table 1: Surface antigen density impacts in vitro potency of anti-LIV-1 ADC . MCF-7 ATCC cells from three sources with varying levels of LIV-1 expression were tested with SGN-LIV1A for cytotoxicity. Lower antigen density resulted in decreased potency.
Supplementary Table 1 from Targeted Silencing of MLL5β Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers
Authors: Nin Dawn Sijin , Yew Chow Wenn , Tay Sun Kuie , Deng Lih-Wen
Published: April 2023

Supplementary Table 1: Sequences of siRNAs used
Supplementary Tables and Methods from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Authors: Mazumdar Tuhina , Byers Lauren A. , Ng Patrick Kwok Shing , Mills Gordon B. , Peng Shaohua , Diao Lixia , Fan You-Hong , Stemke-Hale Katherine , Heymach John V. , Myers Jeffrey N. , Glisson Bonnie S. , Johnson Faye M.
Published: April 2023

Supplementary Tables and Methods
Supplementary Figure 3 from The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Authors: Kim Jeong Min , Jeung Hei-Cheul , Rha Sun Young , Yu Eun Jeong , Kim Tae Soo , Shin You Keun , Zhang Xianglan , Park Kyu Hyun , Park Seung Woo , Chung Hyun Cheol , Powis Garth
Published: April 2023

Supplementary Figure 3: Adhesion assay after treatment of RAV-18.
Supplementary Figure and Table Legends from Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Authors: Onstenk Wendy , Kraan Jaco , Mostert Bianca , Timmermans Mieke M. , Charehbili Ayoub , Smit Vincent T.H.B.M. , Kroep Judith R. , Nortier Johan W.R. , van de Ven Saskia , Heijns Joan B. , Kessels Lonneke W. , van Laarhoven Hanneke W.M. , Bos Monique M.E.M. , van de Velde Cornelis J.H. , Gratama Jan W. , Sieuwerts Anieta M. , Martens John W.M. , Foekens John A. , Sleijfer Stefan
Published: April 2023

Legends to supplementary table 1 and figure 1
Supplementary Figure S6 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S6. Immunohistochemistry of cleaved caspase 3
Supplementary Figure 6. Effects of caspase inhibitors alone on myeloma cell viability. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

As in Figure 3E of the main text, MM1.S and RPMI 8226 cells were treated for 24 hours with caspase 9 inhibitor (LEHD; 50 µM), pan-caspase inhibitor, Q-VD-OPH, (VD; 25 µM), or caspase 10 inhibitor (AEVD; 25 µM) alone. Relative cell viability was determined using MTT assay.
Figure S1 from Modeling of Patient-Derived Xenografts in Colorectal Cancer
Authors: Katsiampoura Anastasia , Raghav Kanwal , Jiang Zhi-Qin , Menter David G. , Varkaris Andreas , Morelli Maria P. , Manuel Shanequa , Wu Ji , Sorokin Alexey V. , Rizi Bahar Salimian , Bristow Christopher , Tian Feng , Airhart Susan , Cheng Mingshan , Broom Bradley M. , Morris Jeffrey , Overman Michael J. , Powis Garth , Kopetz Scott
Published: April 2023

Hematoxylin and eosin staining showing conformity of grade between patient sample and respective established xenografts from both primary and metastatic sites.
Supplemental Figure 6 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental Figure 6. Loss of p53 function results in decreased radiosensitivity in HNSCC cell lines.
Supplemental Figure 5 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental Figure 5. Acute IR effects on reducing potential and lactate can be used to detect intrinsic radioresistance driven by loss of p53 activity.
Supplemental Figure 4 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental Figure 4. Lactate accumulates in extra-cellular media as a function of cellular metabolism over time.
Supplemental Figure 2 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental Figure 2. IR triggers a temporary, reversible perturbation in cellular reducing potential.
Supplemental Figure 1 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Authors: Sandulache Vlad C. , Chen Yunyun , Skinner Heath D. , Lu Tongtong , Feng Lei , Court Laurence E. , Myers Jeffrey N. , Meyn Raymond E. , Fuller Clifton D. , Bankson James A. , Lai Stephen Y.
Published: April 2023

Supplemental Figure 1. Metabolic inhibition and exogenous ROS perturb cellular reducing potential.
Supplementary Figures 1 and 2 from Protein-Tyrosine Phosphatase H1 Increases Breast Cancer Sensitivity to Antiestrogens by Dephosphorylating Estrogen Receptor at Tyr537
Authors: Suresh Padmanaban S. , Ma Shao , Migliaccio Antimo , Chen Guan
Published: April 2023

PDF - 289K, Figure S1. PTPH1 increases breast cancer sensitivity to TAM; Figure S2. PTPH1 increases breast cancer sensitivity to anti-estrogens.
Supplementary Figure Legends from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary manuscript including supplementary figure legends
Supplementary Video S1 from Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
Authors: Zhang Yilin , Sriraman Shravan Kumar , Kenny Hilary A. , Luther Ed , Torchilin Vladimir , Lengyel Ernst
Published: April 2023

SKOV3-TR untreated
Supplementary Materials and Methods: Generation of IHC Reagent M15-68(2)22 from Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
Authors: Morrison Kendall , Challita-Eid Pia M. , Raitano Arthur , An Zili , Yang Peng , Abad Joseph D. , Liu Wendy , Lortie Dawn Ratay , Snyder Josh T. , Capo Linnette , Verlinsky Alla , Aviña Hector , Doñate Fernando , Joseph Ingrid B.J. , Pereira Daniel S. , Morrison Karen , Stover David R.
Published: April 2023

Details on how the IHC reagent reported in this paper was generated and validated.
Supplementary Figure 1: The effect of metformin on bladder tumorigenesis from High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum
Authors: Liu Zhongbo , Yokoyama Noriko N. , Blair Christopher A. , Li Xuesen , Avizonis Daina , Wu Xue-Ru , Uchio Edward , Youssef Ramy , McClelland Michael , Pollak Michael , Zi Xiaolin
Published: April 2023

Comparison of average body weight and water consumption over time between control and metformin treated male UPII-Ha-ras transgenic mice.
Supplementary Figure S1. Decay chain of thorium-227. from In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
Authors: Hagemann Urs B. , Wickstroem Katrine , Wang Ellen , Shea Adam O. , Sponheim Kristine , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S.
Published: April 2023

Thorium-227 is purified from actinium-227 (227Ac). Thorium-227 decays via its alpha- and beta-emitting daughters to stable nonradioactive 207Pb. The energy emitted at each decay step (in MeV) are summarized. When thorium-227 decays to radium-223, the 3,2-HOPO chelator is unable to retain the daughter nuclide radium-223 which will detach from the antibody-chelator conjugate.
Supplemental Figure 1 from EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib
Authors: De Andrade James P. , Park Jung M. , Gu Vivian W. , Woodfield George W. , Kulak Mikhail V. , Lorenzen Allison W. , Wu Vincent T. , Van Dorin Sarah E. , Spanheimer Philip M. , Weigel Ronald J.
Published: April 2023

Supplemental Figure 1: Knockdown of RET expression with siRNA.
Supplementary Legends from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Supplementary figures and datasets legends
Supplementary Figure S7 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Effect of AKT1 inhibition in vitro on tumor cell proliferation in vivo
Sup Figure 5 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 5. Bcl2 family expression
Sup Figure 4 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 4. GI50 tables
Supplementary Figure S4 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Bioactivity and effect of microvesicles on growth rate using MK-2206 inhibitor in vitro
Sup Figure 1 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 1. BMX expression in SCLC
Supplementary figure legends from Synthesis and Evaluation of the Novel Prostamide, 15-Deoxy, Δ12,14-Prostamide J2, as a Selective Antitumor Therapeutic
Authors: Ladin Daniel A. , Soliman Eman , Escobedo Rene , Fitzgerald Timothy L. , Yang Li V. , Burns Colin , Van Dross Rukiyah
Published: April 2023

Supplementary figure legends
Supplementary Dataset S1 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Lists of analytes (i.e., mRNA transcripts, proteins, metabolites, small RNAs) with concordant behavior
Supplementary Figure 1 from Synthesis and Evaluation of the Novel Prostamide, 15-Deoxy, Δ12,14-Prostamide J2, as a Selective Antitumor Therapeutic
Authors: Ladin Daniel A. , Soliman Eman , Escobedo Rene , Fitzgerald Timothy L. , Yang Li V. , Burns Colin , Van Dross Rukiyah
Published: April 2023

Chemical structure and primary cell validation
Supplemental Figure 5 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Authors: Wagner Michael J. , Mitra Rahul , McArthur Mark J. , Baze Wallace , Barnhart Kirstin , Wu Sherry Y. , Rodriguez-Aguayo Cristian , Zhang Xinna , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Primate coagulation testing
Supplemental Figures S1-S6 and Table S1 from Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61
Authors: Huang Kuan-Chun , Chen Zhihong , Jiang Yimin , Akare Sandeep , Kolber-Simonds Donna , Condon Krista , Agoulnik Sergei , Tendyke Karen , Shen Yongchun , Wu Kuo-Ming , Mathieu Steven , Choi Hyeong-wook , Zhu Xiaojie , Shimizu Hajime , Kotake Yoshihiko , Gerwick William H. , Uenaka Toshimitsu , Woodall-Jappe Mary , Nomoto Kenichi
Published: April 2023

Figure S1. Synthesis of [3H]apratoxin A. Figure S2. Synthesis of C.18-epi-apratoxin A. Figure S3. Apratoxin A in vitro IC50 against panels of human cancer cell lines. Table S1. Summary table for in vivo efficacy studies. Figure S4. Apratoxin A concentration kinetics in plasma and various tissues in A549 human lung cancer xenograft tumor-bearing mice after a single IV dose (1 mg/kg). Figure S5. Apratoxin A and HUN-7293 have different binding sites on the Sec61 complex. Figure S6. Sec61α and Sec61β protein expression levels among different cell lines.
Supplemental Figure 2 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Authors: Wagner Michael J. , Mitra Rahul , McArthur Mark J. , Baze Wallace , Barnhart Kirstin , Wu Sherry Y. , Rodriguez-Aguayo Cristian , Zhang Xinna , Coleman Robert L. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Primate CK and LDH
FigureS3 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Authors: Chanal Marie , Chevallier Pascale , Raverot Véronique , Fonteneau Guillaume , Lucia Kristin , Monteserin Garcia Jose Luis , Rachwan Alexa , Jouanneau Emmanuel , Trouillas Jacqueline , Honnorat Jérôme , Auger Carole , Theodoropoulou Marily , Raverot Gérald
Published: April 2023

In vitro effects of NVP-BEZ235 and NVP-BKM120 treatments on cell viability in W3 primary culture. Cell viability was measured by colorimetric assay with the CCK-8 test. Data are expressed as percentage of control (mean {plus minus} SEM). Data were analyzed statistically by Mann-Whitney test, *P< 0.05 compared with DMSO. One representative experiment out of three independent experiments at least is shown.
suppl. Fig. 4 from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

Olaparib/TMZ-induced G2 arrest.
suppl. Fig. 3 from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

Olaparib synergizes with TMZ to induce cell death and to reduce viability in TC-32 and TC-71 cells.
Supplementary Figure S2 from Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis
Authors: Yang Jie , Qian Shihui , Cai Xueting , Lu Wuguang , Hu Chunping , Sun Xiaoyan , Yang Yang , Yu Qiang , Gao S. Paul , Cao Peng
Published: April 2023

CS-â…£a-Be inhibits IL-6 binding to its surface IL-6 receptor in MDA-MB-231, Hela and HepG2 cells
Table S2 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

Supplementary Table S2. Immunoblotting antibodies
Figure S7 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Effect of flow field on viability of PSMA-positive HUVEC as a function of delivered radioactivity per cell.
Table S1 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

Characteristics of human lung cancer cell lines used in this study and MTS assay data
Figure S5 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Viability (evaluated after one doubling time) of PSMA-positive HUVEC in monolayers after treatment by targeted radiolabeled constructs.
Figure S5 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

BMS-906024 enhances the anti-tumor activity of paclitaxel in vivo.
Figure S4 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Effect of the presence of CCM on PSMA expression over time.
Figure S4 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

In vivo tumor growth curves of NSCLC cell line- or patient-derived xenografts.
Figure S3 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

Synergy between paclitaxel and BMS-906024 is not modulated by either activated Notch1 or Notch3 overexpression.
Figure S2 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Dissociation constants for targeted vesicle constructs.
Figure S1 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Effect on vesicles' targeting of the content of urea-based PSMA targeting ligand, and structure of the non active targeting construct (negative control) and of the free urea-based ligand.
Supplementary Methods and Supplementary Figures S1-S13 from Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
Authors: Gabrielli Brian , Bokhari Fawzi , Ranall Max V. , Oo Zay Yar , Stevenson Alexander J. , Wang Weili , Murrell Melanie , Shaikh Mushfiq , Fallaha Sora , Clarke Daniel , Kelly Madison , Sedelies Karin , Christensen Melinda , McKee Sara , Leggatt Graham , Leo Paul , Skalamera Dubravka , Soyer H. Peter , Gonda Thomas J. , McMillan Nigel A.J.
Published: April 2023

Contains siRNA primary screen analysis and subsequent supplemental analyses; Figure S1 Analysis was performed using customized R scripts and proceeded via a three step process; Figure S2 Summary of Z scores of the top 54 selected target hits from the primary screen were rescreened using OnTarget Plus siRNAs; Figure S3 Mitosis is not a general target in HPV-transformed cancer cell lines; Figure S4A. Dose response for all the cell lines with the Aurora B inhibitor ZM447439; Figure S4B. Flow cytometry of the DNA content of cells were treated with 5 μM ZM447439 and collected at 24, 48, and 72 h, using DMSO as a control; Figure S5: Either wild type or K14E7 transgenic skin grafted onto wild type mice, either treated with Alisertib in vivo or untreated, was stained for mast cells using touluidine blue; Figure S6: Alisertib treatment of HPV-transformed cancer cells promotes apoptosis; Figure S7A. HPV- and non-HPV-transformed cancer cells were treated with 5 μM Alisertib and sampled at intervals over 72 h and analysed by flow cytometry for DNA content; S7B. Immunofluorescence of representative HPV-transformed (HeLa) and non-HPV C33A cells treated with DMSO (Control) or 5μM of Alisertib for 48 h stained for DNA and microtubules (α-tubulin). S7C. Quantitation of bi-nucleated and multinucleated cells in control and Alisertibtreated cells for 1 and 2 days; Figure S8 Representative time-lapse series of HeLa and C33A with and without 5 μM Alisertib treatment transiting mitosis and undergoing apoptosis; Figure S9: The time lines for 50 HeLa and 50 CaSki cells treated with 5 μM Alisertib; Figure S10: The dose response of parental HeLa cells and HeLa cells over expressing either Bcl-2 or Mcl- 1 with etoposide and Taxol, respectively, are shown; Figure S11: HPV-transformed ME180 and non-HPV C33A cells were treated with 5 μM Alisertib for up to 3 days; Figure S12 Dose response curves for HPV16 E7 expressing C33A and SCC25 cell lines determined (one of four replicate experiments); Figure S13: FACS of the GFP levels in the HPV18 E7-IRES-GFP transduced SCC25 cell lines used in Figure 7B, C.
Supplementary Figure 6 from Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
Authors: Collet Guillaume , Lamerant-Fayel Nathalie , Tertil Magdalena , El Hafny-Rahbi Bouchra , Stepniewski Jacek , Guichard Alan , Foucault-Collet Alexandra , Klimkiewicz Krzysztof , Petoud Stéphane , Matejuk Agata , Grillon Catherine , Jozkowicz Alicja , Dulak Jozef , Kieda Claudine
Published: April 2023

PDF - 1037KB, Effect of the IFP1.4 and mCherry expression on the B16F10 cells proliferation.
Supplemental Figures S1-S7; Supplemental Materials and Methods; and Supplemental Table S1 from ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme
Authors: Cherry Allison E. , Haas Brian R. , Naydenov Alipi V. , Fung Susan , Xu Cong , Swinney Katie , Wagenbach Michael , Freeling Jennifer , Canton David A. , Coy Jonathan , Horne Eric A. , Rickman Barry , Vicente Juan Jesus , Scott John D. , Ho Rodney J.Y. , Liggitt Denny , Wordeman Linda , Stella Nephi
Published: April 2023

Figure S1: Representative histological features of orthotropic DBT tumor 3 weeks after implantation Figure S2: Semi-quantitative analysis of microglial invasion of DBT tumors Figure S3: ST-11 reduces proliferation and triggers apoptosis in DBT cells in vitro Figure S4: ST-11 leaves interphase MT tips intact and mediates reversible effects on MT assembly Figure S5: ST-11 activates apoptosis in cultured T98G and DBT cells Figure S6: Paclitaxel reduces the viability of MDA-MB-231 cells Figure S7: Solubility and stability of ST-11 Movies: MT dynamics in T98G cells Supplemental materials & methods containing detailed experimental procedures Table S1: Response of T98G cells to 10 AI analogues as measured with WST-1
Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
Authors: Hisamatsu Takeshi , McGuire Michael , Wu Sherry Y. , Rupaimoole Rajesha , Pradeep Sunila , Bayraktar Emine , Noh Kyunghee , Hu Wei , Hansen Jean M. , Lyons Yasmin , Gharpure Kshipra M. , Nagaraja Archana S. , Mangala Lingegowda S. , Mitamura Takashi , Rodriguez-Aguayo Cristian , Eun Young Gyu , Rose Johnathon , Bartholomeusz Geoffrey , Ivan Cristina , Lee Ju-Seog , Matsuo Koji , Frumovitz Michael , Wong Kwong K. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Table S1 shows antibody concentrations. Table S2 shows siRNA sequences. Table S3 shows qPCR primers sequences. Table S5 shows IC50 values of oxaliplatin.
Supplementary Figure S7 from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

Densitometric quantitation of AR and PSA protein expression (for data shown in Fig. 5C of the main text) in 22Rv1, LNCaP, and PC3-AR cells after treatment with LLM-ITC.
Figure S1 to S15 from Involvement of Prokineticin 2–expressing Neutrophil Infiltration in 5-Fluorouracil–induced Aggravation of Breast Cancer Metastasis to Lung
Authors: Sasaki Soichiro , Baba Tomohisa , Muranaka Hayato , Tanabe Yamato , Takahashi Chiaki , Matsugo Seiichi , Mukaida Naofumi
Published: April 2023

Figure S1: 5-FU-induced increase in lung metastasis of TS/A. Figure S2: Effects of 5-FU treatment on cells infiltrating into lungs. Figure S3: Characterization of CD11b+Ly6G+ cells infiltrated into lung. Figure S4: 5-FU effects to expression of Cxcl1 and Cxcl2 in lung. Figure S5: Molecular mechanisms underlying 5-FU, CTX and DOX-induced Cxcl1 and Cxcl2 expression in 4T1 and TS/A cells. Figure S6: Molecular mechanisms underlying 5-FU-induced CXCL1, CXCL2, and CXCL8 expression in a human breast cancer cell line, BT-20 cells. Figure S7: Effects of 5-FU treatment on CD11b+Ly6G+ neutrophils in lungs. Figure S8: Reduction in 5-FU-induced increase in lung metastasis by Prokr1 deletion. Figure S9: Schematic demonstration on presumed cellular and molecular mechanisms underlying 5-FU-enhanced lung metastasis of breast cancer. Figure S10: Effect of 5-FU on cell senescence in 4T1 and TS/A cells. Figure S11: Effect of an ATM inhibitor, KU-60019, on Cxcl1 and Cxcl2 expression in 4T1 and TS/A cells. Figure S12: Effect of H2O2 on Cxcl1 and Cxcl2 expression in 4T1 cells. Figure S13: Relation of PROKR1 and PROK2 expression with the prognosis of breast cancer patients. Figure S14: Effect of Cxcl1, Cxcl2 and G-CSF on Prok2 expression in CD11b+Ly6G+ neutrophils. Figure S15: Effect of 5-FU on G-csf expression in lung tissue.
Supplementary Figure S1. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

LLM treatment inhibited viability and AR expression in Myc-CaP cells.
Supplementary Figures S1-10 and Table S1 from EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
Authors: Viswanadhapalli Suryavathi , Luo Yiliao , Sareddy Gangadhara R. , Santhamma Bindu , Zhou Mei , Li Mengxing , Ma Shihong , Sonavane Rajni , Pratap Uday P. , Altwegg Kristin A. , Li Xiaonan , Chang Annabel , Chávez-Riveros Alejandra , Dileep Kalarickal V. , Zhang Kam Y.J. , Pan Xinlei , Murali Ramachandran , Bajda Marek , Raj Ganesh V. , Brenner Andrew J. , Manthati Vijaya , Rao Manjeet K. , Tekmal Rajeshwar R. , Nair Hareesh B. , Nickisch Klaus J. , Vadlamudi Ratna K.
Published: April 2023

Supplementary Figure S1 shows SPR studies and Biotin EC359 pull down assays; Supplementary Figure S2 shows superimposition of hLIFR onto the mLIFR -hLIF complex; Supplementary Figure S3 shows sequence alignment of human (P42702) and mouse (P42703) LIFR ; Supplementary Figure S4 shows five prominent sites identified through sitemap program Schrödinger; Supplementary Figure S5 shows binding poses of EC359 at Site-3; Supplementary Figure S6 shows MM-GBSA scores for different poses obtained from the IFD; Supplementary Figure S7 shows ligand induced conformational changes in the best scored pose; Supplementary Figure S7 shows ligand induced conformational changes in the best scored pose; Supplementary Figure S8 shows the RMSD of protein and ligand; Supplementary Figure S9 shows pharmacological features of EC359; Supplementary Figure S10 shows effect of dox inducible CRISPR/Cas9 mediated KO of LIFR on STAT3 signaling and effect of EC359 on self-renewal of stem cells; Supplementary Table 1 shows primer sequences used for RT-qPCR analysis.
Supplementary methods from In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Authors: Hughes Paul E. , Rex Karen , Caenepeel Sean , Yang Yajing , Zhang Yihong , Broome Martin A. , Kha Hue T. , Burgess Teresa L. , Amore Benny , Kaplan-Lefko Paula J. , Moriguchi Jodi , Werner Jonathan , Damore Michael A. , Baker Daniel , Choquette Deborah M. , Harmange Jean-Christophe , Radinsky Robert , Kendall Richard , Dussault Isabelle , Coxon Angela
Published: April 2023

Supplementary methods of tumor xenograft studies and light microscopic evaluation of tumor xenografts
Supplementary Data File 2 from In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Authors: Hughes Paul E. , Rex Karen , Caenepeel Sean , Yang Yajing , Zhang Yihong , Broome Martin A. , Kha Hue T. , Burgess Teresa L. , Amore Benny , Kaplan-Lefko Paula J. , Moriguchi Jodi , Werner Jonathan , Damore Michael A. , Baker Daniel , Choquette Deborah M. , Harmange Jean-Christophe , Radinsky Robert , Kendall Richard , Dussault Isabelle , Coxon Angela
Published: April 2023

Tumor cell line profiling data
Supplementary Table S1 from APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer
Authors: Tanaka Noritaka , Mashima Tetsuo , Mizutani Anna , Sato Ayana , Aoyama Aki , Gong Bo , Yoshida Haruka , Muramatsu Yukiko , Nakata Kento , Matsuura Masaaki , Katayama Ryohei , Nagayama Satoshi , Fujita Naoya , Sugimoto Yoshikazu , Seimiya Hiroyuki
Published: April 2023

IC50 values of colorectal cancer cell lines and colorectal cancer patient-derived cells
Table S1 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

Material list
Supplementary Material & Method from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

Supplementary Material & Method
Figure S1, Figure S2, Figure S3 from Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
Authors: Floc'h Nicolas , Lim Sangbin , Bickerton Sue , Ahmed Afshan , Orme Jonathan , Urosevic Jelena , Martin Matthew J. , Cross Darren A.E. , Cho Byoung Chul , Smith Paul D.
Published: April 2023

Supplementary Figure 1: Osimertinib monotherapy induce tumor growth inhibition in a NSCLC EGFR G719A;S768I mutation PDX model in vivo. Supplementary Figure 2: Osimertinib as monotherapy induce a stronger inhibition of the level of pEGFR and the downstream signalling pathways than afatinib. Supplementary Figure 3: MET amplification induces resistance to osimertinib treatment in a NSCLC EGFR G719A mutation PDX model in vivo.
Supplementary Figure 6 from A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment
Authors: Kuang Zhihui , Pu Pu , Wu Min , Wu Zhihai , Wang Li , Li Yiming , Zhang Shaofei , Jing Hua , Wu Weiwei , Chen Bingliang , Liu Junjian
Published: April 2023

PK in mice
Figure S1 from Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
Authors: Strickler John H. , LoRusso Patricia , Salgia Ravi , Kang Yoon-Koo , Yen Chia Jui , Lin Chia-Chi , Ansell Peter , Motwani Monica , Wong Shekman , Yue Huibin , Wang Lan , Reilly Edward , Afar Daniel , Naumovski Louie , Ramanathan Ramesh K.
Published: April 2023

Progression-free survival in MET-amplified patients
Fig. S3 from Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK
Authors: Pucciarelli Daniela , Angus Steven P. , Huang Benjamin , Zhang Chi , Nakaoka Hiroki J. , Krishnamurthi Ganesh , Bandyopadhyay Sourav , Clapp D. Wade , Shannon Kevin , Johnson Gary L. , Nakamura Jean L.
Published: April 2023

Supplementary Figure 3
Supplementary Data from Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
Authors: Ohol Yamini M. , Sun Michael T. , Cutler Gene , Leger Paul R. , Hu Dennis X. , Biannic Berenger , Rana Payal , Cho Cynthia , Jacobson Scott , Wong Steve T. , Sanchez Jerick , Shah Niket , Pookot Deepa , Abraham Betty , Young Kyle , Suthram Silpa , Marshall Lisa A. , Bradford Delia , Kozon Nathan , Han Xinping , Okano Akinori , Maung Jack , Colas Christophe , Schwarz Jacob , Wustrow David , Brockstedt Dirk G. , Kassner Paul D.
Published: April 2023

Supplementary Figures S1-S6 and legends, and Tables S1, S2, S5, S6, S7.
Table S11-14 from PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis
Authors: Lim James T. , Singh Neha , Leuvano Libia A. , Calvert Valerie S. , Petricoin Emanuel F. , Teachey David T. , Lock Richard B. , Padi Megha , Kraft Andrew S. , Padi Sathish K.R.
Published: April 2023

Table S11: RPPA differential abundance in AZD1208 resistant compared to DMSO treated HSB-2 cells. Table S12: RPPA differential abundance in AZD-1µM (AZD1208 sensitive) compared to AZDR1 HSB-2 cells. Table S13: RPPA differential abundance in LGB321 resistant compared to DMSO treated HSB-2 cells. Table S14: RPPA differential abundance in LGB-1µM (LGB321 sensitive) compared to LGBR2 HSB-2 cells.
Supplementary Data Table S4 from Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase
Authors: McDonald Gabrielle , Chubukov Victor , Coco John , Truskowski Kevin , Narayanaswamy Rohini , Choe Sung , Steadman Mya , Artin Erin , Padyana Anil K. , Jin Lei , Ronseaux Sebastien , Locuson Charles , Fan Zi-Peng , Erdmann Tabea , Mann Alan , Hayes Sebastian , Fletcher Mark , Nellore Kavitha , Rao Siva Sanjeeva , Subramanya Hosahalli , Reddy K. Satish , Panigrahi Sunil K. , Antony Thomas , Gopinath Sreevalsam , Sui Zhihua , Nagaraja Nelamangala , Dang Lenny , Lenz Georg , Hurov Jonathan , Biller Scott A. , Murtie Josh , Marks Kevin M. , Ulanet Danielle B.
Published: April 2023

X-ray data collection and refinement statistics for DHODHâ€¢FMNâ€¢OROâ€¢AG-636
Supplementary Data from Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
Authors: Udhane Vindhya , Maranto Cristina , Hoang David T. , Gu Lei , Erickson Andrew , Devi Savita , Talati Pooja G. , Banerjee Anjishnu , Iczkowski Kenneth A. , Jacobsohn Kenneth , See William A. , Mirtti Tuomas , Kilari Deepak , Nevalainen Marja T.
Published: April 2023

Supplementary Material and Methods
Supplementary Fig S7 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S7. A, Western blot showing the effects of HeSPs on the protein levels of SLC48A1 in NSCLC H1299 tumors. B, Western blot showing the effects of HeSP and HeSP2pf on the protein levels of SLC48A1 in NSCLC H1299 tumors and quantified SLC48A1 levels calculated from three independent tumor samples. C, Western blot showing the effects of HeSPs on the protein levels of SLC40A1 in NSCLC H1299 tumors. Images for A and C were from the same blot (reused after stripping the first antibody used), so the the image for ï�¢-actin is the same. D, Western blot showing the effects of HeSP and HeSP2pf on the protein levels of SLC40A1 in NSCLC H1299 tumors and quantified SLC48A1 levels calculated from three independent tumor samples. E, Western blot showing the effects of HeSPs on the protein levels of GLS in NSCLC H1299 tumors. F, Western blot showing the effects of HeSP and HeSP2pf on the protein levels of GLS in NSCLC H1299 tumors and quantified SLC48A1 levels calculated from three independent tumor samples. Images for B and F were from the same blot, so the image for ï�¢-actin is the same. G, The effects of HeSP2 treatment on glucose consumption in NSCLC H1299 and A549 cells. H, The effects of HeSP2 treatment on glucose consumption in NSCLC H1299 and A549 cells. Protein, glucose, and glutamine levels were quantified. Data were plotted as mean {plus minus} SEM. *, P <â€‰0.05; **, P < 0.01; ***, P < 0.005.
Supplementary Data from PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
Authors: Casazza Andrea , Van Helleputte Lawrence , Van Renterghem Britt , Pokreisz Peter , De Geest Natalie , De Petrini Marzia , Janssens Tom , Pellens Marijke , Diricx Marjan , Riera-Domingo Carla , Wozniak Agnieszka , Mazzone Massimiliano , Schöffski Patrick , Defert Olivier , Reyns Geert , Kindt Nele
Published: April 2023

Supplementary Data from PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
Data from Studies on Mechanism of Action of Anticancer Peptides by Modulation of Hydrophobicity Within a Defined Structural Framework
Authors: Huang Yi-bing , Wang Xiao-fei , Wang Hong-ye , Liu Yu , Chen Yuxin
Published: April 2023

Abstract
In the present study, the hydrophobicity of a 26-residue α-helical peptide (peptide P) was altered to study the effects of peptide hydrophobicity on the mechanism of action of cationic anticancer peptides. Hydrophobicity of the nonpolar face of the peptides was shown to correlate with peptide helicity. The self-association ability of peptides in aqueous environment, determined by the reversed-phase high performance liquid chromatography temperature profiling, showed strong influence on anticancer activity. The peptide analogues with greater hydrophobicity showed stronger anticancer activity determined by IC50 values with a necrotic-like membrane disruption mechanism. Peptide analogues exhibited high specificity against cancer cells and much higher anticancer activity than widely-used anticancer chemical drugs. The mechanism of action of anticancer peptides was also investigated. The hydrophobicity of peptides plays a crucial role in the mechanism of action against cancer cells, which could present a way, using a de novo design approach, to create anticancer peptides as potential therapeutics in clinical practices. Mol Cancer Ther; 10(3); 416–26. ©2011 AACR.
Data from Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development
Authors: Hill Reginald , Li Yunfeng , Tran Linh M. , Dry Sarah , Calvopina Joseph Hargan , Garcia Alejandro , Kim Christine , Wang Ying , Donahue Timothy R. , Herschman Harvey R. , Wu Hong
Published: April 2023

Abstract
COX-2 is upregulated in pancreatic ductal adenocarcinomas (PDAC). However, how COX-2 promotes PDAC development is unclear. While previous studies have evaluated the efficacy of COX-2 inhibition via the use of nonsteroidal anti-inflammatory drugs (NSAID) or the COX-2 inhibitor celecoxib in PDAC models, none have addressed the cell intrinsic versus microenvironment roles of COX-2 in modulating PDAC initiation and progression. We tested the cell intrinsic role of COX-2 in PDAC progression using both loss-of-function and gain-of-function approaches. Cox-2 deletion in Pdx1+ pancreatic progenitor cells significantly delays the development of PDAC in mice with K-ras activation and Pten haploinsufficiency. Conversely, COX-2 overexpression promotes early onset and progression of PDAC in the K-ras mouse model. Loss of PTEN function is a critical factor in determining lethal PDAC onset and overall survival. Mechanistically, COX-2 overexpression increases p-AKT levels in the precursor lesions of Pdx1+; K-rasG12D/+; Ptenlox/+ mice in the absence of Pten LOH. In contrast, Cox-2 deletion in the same setting diminishes p-AKT levels and delays cancer progression. These data suggest an important cell intrinsic role for COX-2 in tumor initiation and progression through activation of the PI3K/AKT pathway. PDAC that is independent of intrinsic COX-2 expression eventually develops with decreased FKBP5 and increased GRP78 expression, two alternate pathways leading to AKT activation. Together, these results support a cell intrinsic role for COX-2 in PDAC development and suggest that while anti-COX-2 therapy may delay the development and progression of PDAC, mechanisms known to increase chemoresistance through AKT activation must also be overcome. Mol Cancer Ther; 11(10); 2127–37. ©2012 AACR.
Data from Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma
Authors: McFarland Braden C. , Ma Jing-Yuan , Langford Catherine P. , Gillespie G. Yancey , Yu Hao , Zheng Ying , Nozell Susan E. , Huszar Dennis , Benveniste Etty N.
Published: April 2023

Abstract
Aberrant activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been implicated in glioblastoma (GBM) progression. To develop a therapeutic strategy to inhibit STAT-3 signaling, we have evaluated the effects of AZD1480, a pharmacologic inhibitor of JAK1 and JAK2. In this study, the in vitro efficacy of AZD1480 was tested in human and murine glioma cell lines. AZD1480 treatment effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis. Furthermore, we used human xenograft GBM samples as models for the study of JAK/STAT-3 signaling in vivo, because human GBM samples propagated as xenografts in nude mice retain both the hallmark genetic alterations and the invasive phenotype seen in vivo. In these xenograft tumors, JAK2 and STAT-3 are constitutively active, but levels vary among tumors, which is consistent with the heterogeneity of GBMs. AZD1480 inhibits constitutive and stimulus-induced phosphorylation of JAK2 and STAT-3 in these GBM xenograft tumors in vitro, downstream gene expression, and inhibits cell proliferation. Furthermore, AZD1480 suppresses STAT-3 activation in the glioma-initiating cell population in GBM tumors. In vivo, AZD1480 inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial GBM tumors by inhibiting STAT-3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by AZD1480 should be considered for study in the treatment of patients with GBM tumors. Mol Cancer Ther; 10(12); 2384–93. ©2011 AACR.